As shown in Table 2, increased MSH6 and MLH1 mRNA levels were associated with a better OS in stage III + IV ovarian cancer patients, high mRNA levels of PMS2 implied an improved OS either in stage I + II or stage III + IV ovarian cancer patients. This evidence concerns the gene MLH1 and ovarian cancer.